论文部分内容阅读
乳腺干细胞对组织自稳态的维持和乳腺癌的发生有至关重要的作用,然而人们对乳腺干细胞的了解仍然非常贫乏。三阴性(雌激素、孕激素、生长素受体阴性)乳腺癌是源于干细胞的乳腺病变,由于没有已知的分子标记,至今临床治疗上没有有效的干预手段。以中国科学院干细胞先导专项为依托,曾艺实验室开展了系统的研究,获得了一系列前沿性进展:发现了乳腺干细胞赖以自我更新的关键微环境因子,建立并优化了能够筛选乳腺干细胞关键基因的体外培养体系;发现了乳腺干细胞的表面特异标记分子,探索了乳腺干细胞性质及其与三阴性乳腺癌病变的关系,为乳腺癌的靶向治疗提供了潜在的新靶点和理论基础。主要对干细胞先导专项中曾艺实验室的原创性工作进行综述。
Mammary stem cells play an important role in the maintenance of tissue homeostasis and the development of breast cancer. However, the understanding of breast stem cells is still poor. Triple-negative (estrogen, progesterone, and auxin receptor-negative) breast cancers are breast lesions derived from stem cells. There are no known molecular markers, and there are no effective interventions for clinical treatment so far. Based on the Stem Cell Initiative of the Chinese Academy of Sciences, Zengyi Lab conducted a systematic study and obtained a series of cutting-edge advances: the key micro-environmental factors for the self-renewal of mammary stem cells were discovered, and the key to the selection and screening of mammary stem cells was established and optimized. The in vitro culture system of genes; the discovery of specific surface marker molecules of mammary stem cells, exploring the nature of mammary stem cells and its relationship with triple-negative breast cancer lesions, providing potential new targets and theoretical basis for targeted therapy of breast cancer. The author summarizes the original work of Zengyi Laboratories in Stem Cell Pilot Project.